CD8A and telomere syndrome: Doxorubicin is often used in the treatment of STS patients24; it induces immunogenic cell death leading to increased antigen presentation by dendritic cells to CD8+ T cells in the tumor-draining lymph node, thereby triggering a cytotoxic T cell response within the tumor mass59.